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ELECTROACTIVE SUPRAMOLECULAR assemblies , compositions , apparatus , methods , features and 
POLYMERIC ASSEMBLIES , METHODS OF advantages be included within this description , be within the 
MAKING ELECTROACTIVE scope of the present disclosure , and be protected by the 
SUPRAMOLECULAR POLYMERIC accompanying claims . 
ASSEMBLIES , AND METHOD OF USING 
ELECTROACTIVE SUPRAMOLECULAR BRIEF DESCRIPTION OF THE DRAWINGS 
POLYMERIC ASSEMBLIES 
Further aspects of the present disclosure will be more 
CROSS - REFERENCE TO RELATED readily appreciated upon review of the detailed description 
APPLICATIONS 10 of its various embodiments , described below , when taken in 
conjunction with the accompanying drawings . 
This application is the 35 U.S.C. § 371 national stage FIG . 1 illustrates camphorsulfonic acid ( CSA ) and dex 
application of PCT Application No. PCT / US2016 / 035227 amethasone phosphate ( DMP ) . 
filed Jun . 1 , 2016 , where the PCT claims the benefit of and FIG . 2 shows DMP release from films of MTT1 and priority to U.S. Provisional Application Ser . No. 62 / 170,742 , 15 MTT2 in the absence and presence of electrical stimulation having the title “ ELECTROACTIVE SUPRAMOLECU as determined by UV spectroscopy . MTT1 without electrical LAR POLYMERIC ASSEMBLIES , METHODS OF MAK stimulation is illustrated with checked grey bars ; MTT1 with ING ELECTROACTIVE SUPRAMOLECULAR POLY 
MERIC ASSEMBLIES , AND METHODS OF USING electrical stimulation solid grey bars ; MTT2 without elec trical is illustrated with stimulation checked black bars ; ELECTROACTIVE SUPRAMOLECULAR POLYMERIC 20 MTT2 with electrical stimulation is illustrated with solid ASSEMBLIES , ” filed on Jun . 4 , 2015 , both of which are black bars . herein incorporated by reference in their entireties . FIG . 3A is a graph of assessment of the cell viability of 
BACKGROUND human dermal fibroblasts on various surfaces after 2 days in 
25 culture as determined using a LIVE / DEAD® Viability / 
Technologies that enable precise control of the amount of Cytotoxicity Kit . FIG . 3B is a graph of assessment of cell 
drugs in the blood stream or specific tissues facilitate the adhesion on various surfaces after 2 days as determined by 
maintenance of the amount of drug within the therapeutic the AlamarBlue® assay . 
window , and controlling the chronopharmacology of a drug FIGS . 4A - D shows adhesion of human dermal fibroblasts 
are particularly useful for the treatment of diseases with 30 on various surfaces after 4 days in culture : FIG . 4A ) 
specific chronobiologies . Thus there is a need for material to Undoped MTT1 , FIG . 4B ) CSA - doped MTT1 , FIG . 4C ) 
accomplish these and other similar goals . Undoped MTT2 , and FIG . 4D ) CSA - doped MTT2 . Live 
cells were stained green by calcein and dead cells were 
SUMMARY stained red by ethidium using a LIVE / DEAD® Viability / 
35 Cytotoxicity Kit . Scale bars represent 100 um . 
Embodiments of the present disclosure provide for elec FIGS . 5A - D are FTIR spectra of the electroactive molecu 
troactive supramolecular polymeric assemblies , methods of lar tongue twisters : FIG . 5A ) MTT1 undoped , FIG . 5B ) 
making electroactive supramolecular polymeric assemblies , MTT1 doped with CSA , FIG . 5C ) MTT2 undoped , and FIG . 
methods of using electroactive supramolecular polymeric 5D ) MTT2 doped with CSA . 
assemblies , and the like . FIGS . 6A - D are XRD spectra of the electroactive molecu 
An embodiment of the present disclosure includes an lar tongue twisters : FIG . 6A ) MTT1 undoped , FIG . 6B ) 
electroactive supramolecular polymeric assembly , among MTT1 doped with CSA , FIG . 6C ) MTT2 undoped , and FIG . 
others , that includes : an electroactive ABA block copolymer , 6D ) MTT2 doped with CSA . 
where A is a non - electroactive polymer and B is an electro FIG . 7 is a schematic of an experimental setup for 
active polymer . 45 electrochemically - triggered drug delivery . Pt mesh counter 
An embodiment of the present disclosure includes an electrode ( CE ) , Ag / AgCl reference electrode ( RE ) , DMP 
electroactive supramolecular polymeric assembly , among doped polymer film coated on a glass carbon working 
others , that includes : an electroactive ABA block copolymer electrode ( WE ) . 
and an agent , where A is a non - electroactive polymer and B FIG . 8A is a voltammogram of 0.6 mM ferrocenemetha 
is an electroactive polymer , wherein A is a non - electroactive 50 nol in 0.1 M KC1 . Scan rate = 10 mV s - 1 . See the literature or 
oligoalanine and B is an electroactive oligoaniline , wherein a comparison : A. Heras , A. Colina , J. Lopez - Palacios , A. 
the agent is selected from the group consisting of : a drug , a Kaskela , A. Nasibulin , V. Ruiz , E. Kauppinen , Electrochem . 
therapeutic agent , a radiological agent , a chemological Commun . 2009 , 11 , 442-445 . FIG . 8B is a voltammogram of 
agent , a small molecule drug , a biological agent , and com DMP - doped MTT1 . Scan rate = 50 mV s - 1 . FIG . 8C is a 
binations thereof . 55 voltammogram of DMP - doped MTT2 . Scan rate = 50 mV 
An embodiment of the present disclosure includes a s - 1 . 
method of delivering an agent , among others , that includes : FIG . 9 shows HDF adhesion on the surface of Corning 
providing an electroactive ABA block copolymer including Costar® Tissue Culture Plates ( TCP control ) . Live cells 
an agent to a subject ; providing an electrical stimulus to the were stained green by calcein and dead cells were stained 
electroactive ABA block copolymer ; and releasing the agent , 60 red by ethidium using a LIVE / DEAD® Viability / Cytotox 
wherein application of the electrical stimulus causes the icity Kit . The scale bar represents 100 um . 
agent to be released from the electroactive ABA block 
copolymer DETAILED DESCRIPTION 
Other assemblies , compositions , methods , features , and 
advantages will be or become apparent to one with skill in 65 This disclosure is not limited to particular embodiments 
the art upon examination of the following drawings and described , and as such may , of course , vary . The terminology 
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embodiments only , and is not intended to be limiting , since amount that will prevent , to some extent , one or more of the 
the scope of the present disclosure will be limited only by symptoms of the disease that the host being treated has or is 
the appended claims . at risk of developing 
Where a range of values is provided , each intervening The therapeutically effective amount may vary depending 
value , to the tenth of the unit of the lower limit unless the 5 upon the intended application ( in vitro or in vivo ) , or the 
context clearly dictates otherwise , between the upper and subject and disease condition being treated , e.g. , the weight 
lower limit of that range and any other stated or intervening and age of the subject , the severity of the disease condition , 
value in that stated range , is encompassed within the dis the manner of administration and the like , which can readily 
closure . The upper and lower limits of these smaller ranges be determined by one of ordinary skill in the art . The specific 
may independently be included in the smaller ranges and are 10 dose will vary depending on the particular agent chosen , the 
also encompassed within the disclosure , subject to any dosing regimen to be followed , whether it is administered in combination with other agents , timing of administration , the specifically excluded limit in the stated range . Where the tissue to which it is administered , and the physical delivery stated range includes one or both of the limits , ranges system in which it is carried . 
excluding either or both of those included limits are also The term " unit dosage form , " as used herein , refers to included in the disclosure . physically discrete units suitable as unitary dosages for 
As will be apparent to those of skill in the art upon reading human and / or animal subjects , each unit containing a pre 
this disclosure , each of the individual embodiments determined quantity of the agent calculated in an amount described and illustrated herein has discrete components and sufficient to produce the desired effect in association with a 
features which may be readily separated from or combined 20 pharmaceutically acceptable diluent , carrier or vehicle . The 
with the features of any of the other several embodiments specifications for unit dosage forms depend on the particular 
without departing from the scope or spirit of the present agent employed , the route and frequency of administration , 
disclosure . Any recited method may be carried out in the and the effect to be achieved , and the pharmacodynamics 
order of events recited or in any other order that is logically associated with each agent in the subject . 
possible . As used herein , a “ pharmaceutical composition ” and a 
Embodiments of the present disclosure will employ , “ pharmaceutical formulation ” are meant to encompass 
unless otherwise indicated , techniques of organic chemistry , embodiments of the present disclosure or agent suitable for biochemistry , microbiology , molecular biology , pharmacol administration to a subject , such as a mammal , especially a 
ogy , medicine , and the like , which are within the skill of the human . In general , a “ pharmaceutical composition ” or 
art . Such techniques are explained fully in the literature . 30 “ pharmaceutical formulation ” is sterile , and preferably free 
of contaminants that are capable of eliciting an undesirable Prior to describing the various embodiments , the follow ing definitions are provided and should be used unless response within the subject ( e.g. , the agent or the polymer assembly in the pharmaceutical composition is pharmaceu 
otherwise indicated . tical grade ) . Pharmaceutical compositions can be designed Unless otherwise defined , all technical and scientific 35 for administration to subjects or patients in need thereof via terms used herein have the same meaning as commonly a number of different routes of administration including oral , 
understood by one of ordinary skill in the art of microbiol intravenous , buccal , rectal , parenteral , intraperitoneal , intra 
ogy , molecular biology , medicinal chemistry , and / or organic dermal , intracheal , intramuscular , subcutaneous , inhala 
chemistry . Although methods and materials similar or tional and the like . 
equivalent to those described herein can be used in the As used herein , the terms “ treatment ” , “ treating ” , and 
practice or testing of the present disclosure , suitable meth “ treat ” are defined as acting upon a condition with an agent 
ods and materials are described herein . to reduce or ameliorate the pharmacologic and / or physi 
As used in the specification and the appended claims , the ologic effects of the condition and / or its symptoms . “ Treat 
singular forms “ a , ” “ an , ” and “ the ” may include plural ment ” , as used herein , covers any treatment of a condition in 
referents unless the context clearly dictates otherwise . Thus , 45 a subject ( e.g. , a mammal , typically a human or non - human 
for example , reference to “ a support includes a plurality of animal of veterinary interest ) , and includes : ( a ) reducing the 
supports . In this specification and in the claims that follow , risk of occurrence of the condition in a subject determined 
reference will be made to a number of terms that shall be to be predisposed to the condition but not yet diagnosed with 
defined to have the following meanings unless a contrary the condition ( b ) impeding the development of the condi 
intention is apparent . 50 tion , and ( c ) relieving the condition , i.e. , causing regression 
of the condition and / or relieving one or more condition 
Definitions symptoms . “ Treatment is also meant to encompass delivery 
of agent or polymer assembly to provide a pharmacologic 
By “ administration ” is meant introducing an electroactive effect , even in the absence of a condition . For example , 
supramolecular polymeric assembly of the present disclo- 55 “ treatment ” encompasses delivery of an agent or polymer 
sure into a subject . The route of administration can include assembly that provides for enhanced or desirable effects in 
any route of administration , such as intravenous oral , topi the subject . 
cal , subcutaneous , peritoneal , intraarterial , inhalation , vagi As used herein , the terms " prophylactically treat ” and 
nal , rectal , nasal , introduction into the cerebrospinal fluid , or " prophylactically treating " refer completely or partially pre 
instillation into body compartments can be used . 60 venting a condition or symptom thereof and / or may be 
The terms “ therapeutically effective amount ” and “ an therapeutic in terms of a partial or complete cure for a 
effective amount ” are used interchangeably herein and refer condition and / or adverse effect attributable to the condition . 
to that amount of an agent being administered that is As used herein , the term “ subject ” includes humans , 
sufficient to effect the intended application including , but not mammals ( e.g. , cats , dogs , horses , etc. ) , birds , and the like . 
limited to , condition treatment . For example , an effective 65 Typical subjects to which embodiments of the present dis 
amount of the agent will relieve to some extent one or more closure may be administered will be mammals , particularly 
of the symptoms of the condition being treated , and / or that primates , especially humans . For veterinary applications , a 
40 
30 
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wide variety of subjects will be suitable , e.g. , livestock such ferrocene , or other units that yield an electroactive product . 
as cattle , sheep , goats , cows , swine , and the like ; poultry In an embodiment that includes oligoaniline , the oligoani 
such as chickens , ducks , geese , turkeys , and the like ; and line can include 1 to 10,000 aniline monomers . 
domesticated animals particularly pets such as dogs and An electrical stimulus can include : contact ( which 
cats . For diagnostic or research applications , a wide variety 5 includes contact in close proximity so that the assembly 
of mammals will be suitable subjects , including rodents receives the electrical stimulus as well as direct contact to ( e.g. , mice , rats , hamsters ) , rabbits , primates , and swine such the electroactive polymer ) of the material with a power 
as inbred pigs and the like . Additionally , for in vitro appli source via a wire ; wireless energy transfer , magnetic force , cations , such as in vitro diagnostic and research applications , mechanical force , light , and / or a chemical that alters the body fluids and cell samples of the above subjects will be 10 redox state of the material . In an embodiment , the electrical 
suitable for use , such as mammalian ( particularly primate stimulus is in direct contact with the material with the power such as human ) blood , urine , or tissue samples , or blood , source . In an embodiment , the electrical stimulus is in urine , or tissue samples of the animals mentioned for vet contact with the material with the power source so that the erinary applications . In some embodiments , a system includes a sample and a host . The term “ living subject ” 15 assembly receives the electrical stimulus where the direct 
refers to the entire subject or organism and not just a part contact may be a short distance away from the assembly . In an embodiment , wireless energy transfer is indirect contact excised ( e.g. , a liver or other organ ) from the living subject . of the power source with the electroactive polymer . The term “ sample ” can refer to a tissue sample , cell A non - electroactive polymer does not respond to the sample , a fluid sample , and the like . The sample may be electrical stimulus in the same manner as the electroactive taken from a host . The tissue sample can include hair 20 polymer responds . In an embodiment , the non - electroactive ( including roots ) , buccal swabs , blood , saliva , semen , polymer can be non - degradable or degradable , and can muscle , or from any internal organs . The fluid may be , but include polyamides / proteins ( e.g. , polyalanine , oligoalanine , is not limited to , urine , blood , ascites , pleural fluid , spinal collagen , and silk ) , polyesters ( e.g. polycaprolactone and fluid , and the like . The body tissue can include , but is not PLLA ) , polysaccharides ( cellulose , chitin , chitosan ) , DNA , limited to , skin , muscle , endometrial , uterine , and cervical 25 RNA , polymers ( e.g. , polyethylyne glycol ) or other units tissue . In the present disclosure , the source of the sample is that yield a non - electroactive product . In an embodiment not critical . that includes oligoalanine , the oligoalanine can include 1 to Supramolecular polymer assemblies are a class of poly 2000 alanine monomers . mers in which the “ monomers ” of the polymers are held In an embodiment , the ABA block copolymer can have together by non - covalent interactions ( e.g. , hydrogen bonds , the following structure : I - stacking , solvophobic interactions , and combinations 
thereof ) . 
Discussion : 
Embodiments of the present disclosure provide for elec 
troactive supramolecular polymeric assemblies , methods of 35 -H , 
making electroactive supramolecular polymeric assemblies , 
methods of using electroactive supramolecular polymeric 
assemblies , and the like . An embodiment of the electroactive 
supramolecular polymeric assembly can include electroac where n is 2 to 10,000 and m + p is 2 to 20,000 . In particular 
tive ABA block copolymers that are conductive upon the 40 embodiments , n is 4 and m + p is 10 or n is 6 and m + p is 26 . 
application of an electrical stimulus . In an embodiment , an In an embodiment , the electroactive supramolecular poly 
agent such as a drug can be associated with ( e.g. , bonded or meric assembly can include one or more agents ( e.g. , a 
bound by ) the electroactive supramolecular polymeric chemical or biological agent ) , where the agent can be 
assembly . In this way , embodiments of the present disclo disposed indirectly or directly ( e.g. , bound or independently 
sure can be used to deliver an agent such as a drug with 45 suspended ) on the electroactive supramolecular polymeric 
clinically relevant chronopharmacologies by applying an assembly . In particular , the agent can include , but is not 
electrical stimulus at a particular time and / or location , which limited to , a drug , a therapeutic agent , a radiological agent , 
can facilitate the treatment of conditions with specific chro a chemological agent , a small molecule drug , a biological 
nobiologies ( e.g. , infectious diseases , pain ) as well as other agent ( e.g. , polypeptides ( e.g. , proteins such as , but not 
conditions . In addition , embodiments of the electroactive 50 limited to , antibodies ( monoclonal or polyclonal ) ) , antigens , 
supramolecular polymeric assemblies can be designed to nucleic acids ( both monomeric and oligomeric ) , polysac 
control the release profiles and cell - biomaterial interactions . charides , haptens , sugars , fatty acids , steroids , purines , 
Embodiments of the electroactive supramolecular poly pyrimidines , ligands , aptamers , and cells ) and combinations 
meric assembly can include electroactive ABA block copo thereof , that can be used to image , detect , study , monitor , 
lymers . In an embodiment , the electroactive ABA block 55 evaluate , treat , and / or screen a condition ( e.g. , a disease , an 
copolymer can include a non - electroactive polymer ( e.g. , infection , an injury , or a related biological event ) of the 
oligomers such as oligoalanines ) as block A and an electro subject . 
active polymer ( e.g. , oligomers such as oligoanilines ) as In an embodiment , the agent is included in an effective 
block B. In an embodiment , the ratio of non - electroactive amount to accomplish its purpose ( e.g. , therapeutically 
oligomers to electroactive oligomers in the block copolymer 60 effective amount ) , can depend upon a variety of factors , 
can be about 1 : 2 to 2 : 1 . Methods of synthesis of ABA block including for example , the age , body weight , general health , 
copolymers are provided in Example 1 . sex , and diet of the subject ; the time of administration ; the 
An electroactive polymer responds to an electrical stimu route of administration ; the rate of excretion of the agent 
lus ( e.g. , a stimulus that actuates , conducts , facilitates ion employed ; the duration of the treatment ; the existence of 
transport , and / or alters the oxidation state of the electroac- 65 other drugs used in combination or coincidental with the 
tive polymer ) . In an embodiment , the electroactive polymer specific composition employed ; and like factors well known 
can include aniline , furan , pyrrole , thiophene , porphyrin , in the medical arts . 
H 
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In general , the agent can be bound to the electroactive cal stimulus can be periodically pulsed . In an embodiment , 
supramolecular polymeric assembly by a physical , biologi the electrical stimulus can be given at certain times of the 
cal , biochemical , mechanical , and / or chemical association day . While embodiments of the present disclosure are directly or indirectly by a suitable means . The term “ bound ” described in connection with the Examples and the corre can include , but is not limited to , chemically bonded ( e.g. , sponding text and figures , there is no intent to limit the 
covalently or ionically ) , biologically bonded , biochemically disclosure to the embodiments in these descriptions . On the 
bonded , and / or otherwise associated with the electroactive contrary , the intent is to cover all alternatives , modifications , 
supramolecular polymeric assembly . In an embodiment , and equivalents included within the spirit and scope of 
being bound can include , but is not limited to , a covalent embodiments of the present disclosure . 
bond , a non - covalent bond , an ionic bond , a chelated bond , Example 
as well as being bound through interactions such as , but not 
limited to , hydrophobic interactions , hydrophilic interac This Example discusses the preparation and characteriza 
tions , charge - charge interactions , - n stacking interactions , tion of films of electroactive supramolecular polymers based on non - electroactive oligoalanines and electroactive oligoa 
combinations thereof , and like interactions . In an embodi 15 nilines . Fibroblasts adhered to and proliferated on the films , 
ment in which the agent is a cell , cell - biomaterial interac and the delivery of the clinically relevant anti - inflammatory 
tions could be controlled through the inclusion of cell drug dexamethasone phosphate could be enhanced upon the 
adhesive peptides ( e.g. , RGD , YIGSR , KQAGDV , application of an electrical stimulus . 
KHIFSDDSSE , KRSR ) , and protease - labile domains ( e.g. , Technologies that enable precise control of the amount of drugs in the blood stream or specific tissues facilitate the APGL , VRN , or indeed oligoalanines such as those in the 20 maintenance of the amount of drug within the therapeutic backbone of MTT1 and MTT2 that are degraded by window , and controlling the chronopharmacology of a drug 
elastase ) . is particularly useful for the treatment of diseases with 
In an embodiment , the electroactive supramolecular poly specific chronobiologies ( e.g. , cancers , infectious diseases , 
meric assembly can be disposed onto a surface to form a film pain ) . Drug delivery systems that respond to chemical 
or layer on the surface . In an embodiment , the electroactive 25 ( e.g. , enzymes , pH ) or physical ( e.g. electric / magnetic fields , light , pH , temperature ) stimuli supramolecular polymeric assembly can be included in a are potentially applicable for the treatment of such condi pharmaceutical formulation . In an embodiment , the electro tions.2,3 Here we report the application of electroactive 
active supramolecular polymeric assembly can be adminis polymers ( EAPs ) that allow drug delivery enhanced by the 
tered to the subject in need ( e.g. , a human patient ) in an application of an electrical stimulus . 
amount so as to provide a therapeutically effective amount 30 EAPs have interesting electronic and optical properties 
of the agent . and are currently investigated for use in electronic4 and 
In an embodiment , the electroactive supramolecular poly biomedical5-8 industries . Polyaniline , polypyrrole and poly 
neri assemblies can be designed to thiophene derivatives are the EAPs most commonly inves ontrol the release tigated for biomedical applications . In recent years block profiles and / or cell - biomaterial interactions by tuning the copolymers incorporating electroactive blocks ( frequently length of the electroactive oligoaniline , the ratio of electro- 35 oligoaniline - based polymers doped with camphorsulfonic 
active to non - electroactive peptide blocks , the identity of the acid , CSA , FIG . 1 ) have been investigated for use as 
non - electroactive peptide ( i.e. , composition and sequence of electroactive tissue scaffolds capable of the electrical stimu 
amino acids ) , and the like . In a particular embodiment , lation of the cells inhabiting them , 11 and as materials for increasing the length of the oligoalanine segments can electrochemically - triggered drug delivery . 12 
render the electroactive supramolecular polymeric assembly 40 used to deliver a variety of drugs , including ; adenosine Polyaniline- and polypyrrole - based systems have been 
more conductive and electrochemically stable ( i.e. , less triphosphate , dexamethasone phosphate ( DMP , FIG . 1 ) , likely to be spontaneously de - doped in biological milieu ) . In DNA , dopamine , nerve growth factor and N - methylphe 
addition , electroactive supramolecular polymeric assemblies nothiazine , as discussed in greater depth in reviews by Garg 
having a higher ratio of electroactive to non - electroactive and co - workers13 and Ndesendo and co - workers . Here we 
peptide blocks can be more conductive . Furthermore , an 45 report the application of electroactive molecular tongue 
embodiment in which a charged amino acid ( s ) is present in twisters ( MTTs ) based on electroactive oligoanilines and 
the electroactive supramolecular polymeric assembly can non - electroactive oligoalanines ( i.e. , oligoalanine - oligoani line - oligoalanine ) for the delivery of dexamethasone phos facilitate the inclusion of cationic drugs ( e.g. , antibacterials phate . The MTTs are solution processable and assemble into and antiarrhythmics ) . hierarchically structured supramolecular polymers 15-21 
As described herein , embodiments of the present disclo- 50 because of hydrogen bonding interactions between the oli 
sure provide for a method of delivering one or more agents . goalanines in the solid state . Such supramolecular polymers 
An embodiment of the method includes providing an elec have prospects for the preparation of conformal electroac 
troactive supramolecular polymeric assembly ( e.g. , an elec tive coatings for implantable biomaterials . 
troactive ABA block copolymer ) including the agent to a The electrochemically responsive blocks of oligoaniline 
subject having a condition ( e.g. , a disease , an infection , an were terminated with amines which enabled the initiation of injury , a syndrome , a disability , a disorder , and a combina ring - opening polymerization of a - amino acid N - carboxyan 
tion thereof ) . The electroactive supramolecular polymeric hydrides , in this case alanine N - carboxyanhydride ( Ala 
assembly can be administered in one or more ways as is best NCA ) . The oligoanilines ( tetraaniline and hexaaniline ) were 
suited for the particular situation . Subsequently , an electrical prepared using the methodology described in the literature 
stimulus can be used to activate electroactive supramolecu ( Scheme 2 ) , as was Ala - NCA ( Scheme 3 ) , 25 and they lar polymeric assembly . In particular , the electronic stimulus 60 were polymerized at room temperature in anhydrous DMF , precipitated in diethyl ether and dried under vacuum 
can be directed to an area where the agent is needed . For ( Scheme 1 ) . The hexafluoroisopropanol ( HFIP ) -soluble 
example , if the condition is pain or an infection at a fraction was extracted and dried under vacuum , yielding 
particular location , the electronic stimulus can be directed to off - white solids that were used without further purification ; 
In this way , the electrical stimulus causes the agent tetraaniline - based molecular tongue - twister 1 ( MTT1 , oli 
to be released from the electroactive supramolecular poly- 65 goalanine - tetraaniline - oligoalanine ) and hexaaniline - based 
meric assembly at or near the location ( e.g. , specific area of molecular tongue - twister 2 ( MTT2 , oligoalanine - hexaaani 
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Scheme 1 : Synthesis of molecular tongue - twisters ( oligoalanine 
oligoaniline - oligoalanine ) from alanine N - carboxyanhydrides and amine 
terminated oligoanilines . a ) DMF , Ar , 96 h . For tetraaniline - based MTT1 , 
n = 4 , and m + p ~ 10 ; whereas for hexaaniline - based MTT2 , n = 6 , and 
26 . 
5 
m + p A 
H2N tay -NH2 
10 
HN 15 
20 D ift 17 
Scheme 2 Synthesis of oligoanilines . 
H2N -NH2 
Et3N , DMSO , 90 ° C. to -NO2 
O2N -NO2 
i ) Sn , HCI , 4h , 80 ° C. 
ii ) NaOH 
iii ) H2O 
H2N -NH2 






i ) Sn , HCI , 4h , 80º C. 
ii ) NaOH 
iii ) H20 






oligoalanine - rich proteins ) . 30-32 The oligoalanine blocks in 
Scheme 3 Synthesis of alanine - N - carboxyanhydride . undoped films of MTT1 assembled into both a - helices 
A ) a - pinene , EtOAc , 90 ° C. , 4h . ( amide I , 1649 cm- ' ) and B - sheets ( amide I , 1692 cm- ' ; 
amide II , 1530 and 1517 cm- ? ) . Doping MTT1 with CSA 
altered the assembly of the MTTs , yet both a - helices ( amide 
I , 1649 cm - 1 ; amide II , 1543 cm- ? ) and B - sheets ( amide 1 , H2N CO2H 1690 cm - 1 , amide II , 1530 and 1514 cm- ? ) were present , 
15 although the B - sheet content was clearly reduced . The 
oligoalanine blocks in undoped films of MTT2 were pre 
dominantly amorphous ( amide I , 1646 cm - 1 ; amide II , 1533 Cl3C . CC13 cm- ? ) with some B - sheets ( amide I , 1629 cm ' ; amide II , 
1518 cm- ? ) . Doping MTT2 with CSA reduced the B - sheet 
20 content ( weak amide I , 1690 cm  - 1 ; weak amide II , 1530 and 
1514 cm - l ) , and the chains were predominantly amorphous 
HN ( amide I , 1646 cm - 1 ; amide II , 1535 cm - 1 ) 27-29 
Wide angle XRD patterns for the films ( FIGS . 6A - D ) 
supported the results from IR spectroscopy , which showed 
evidence of both a - helices ( broad peak at 20 = 19.4o , d - spac ing 4.58 Å ) and B - sheets ( broad peak at 20 = 16.7 ° and 19.9 ° , 
The success of the polymerizations was confirmed spec d - spacings of 5.31 and 4.46 Å , respectively ) also observed 
troscopically . The presence of characteristic peaks in the IR in oligoalanine - rich proteins.29 Films composed of MTT1 
spectra ( FIGS . 5A - D ) for amides and oligoanilines ( shoul showed some peaks reported for tetraniline - based supramo 
ders at ca. 1541 cm- ' ( C = N and C = C stretches ) and 1496 30 lecular polymers ( peaks at 20 = 11.7 ° , 19.5 ° , 20.3 ° , 20.7 ° and 
cm- ? ( C — C stretching ) ) 26 NMR in deuterated HFIP sug 29.7º , d - spacings of 7.56 , 4.55 , 4.37 , 4.29 and 3.01 Å , 
gested that MTT1 incorporated ca. 10 alanine units per respectively ) , 33 and were clearly more crystalline ( higher 
tetraaniline ( in line with the synthesis ) , whereas MTT2 Xc ) than those of CSA - doped MTT1 ( FIGS . 6A - D and Table incorporated 26 alanine units per hexaaniline , suggesting 1 ) because the presence of the bulky CSA anions interfered 
that polymers based on the less soluble hexaaniline required 35 with the assembly of the oligoaniline blocks . 12,34 Films of 
a greater number of alanines for the resulting polymer to be MTT2 were amorphous in both the undoped or CSA - doped 
soluble . Yet their low solubility hampered determination of state . 
the molecular weight distributions via standard techniques The conductance of films of the MTTs were measured as 
such as GPC / SEC , light scattering or MALDI - TOF mass previously reported.12 Undoped films of tetraaniline - based 
spectrometry . MTT1 had a conductivity of ca. 1.6x10-8 S cm- " , that was 
Casting dilute solutions of the MTTs in HFIP allowed the moderately increased by doping with CSA to ca. 2.5x10-8S 
preparation of water insoluble films of a few um in thickness ( Table 1 ) . Undoped films of hexaaniline - based MTT2 
with i um scale roughness ( Ra ) or root mean square roughness had a conductivity of ca. 7.3x10-8 S cm- ?, that was mod ( Rq ) as determined by profilometry ( Table 1 ) . Undoped erately increased by doping with CSA to ca. 8.6x10-8 S 
films were blue , whereas films doped with CSA ( 10 wt % ) ( Table 1 ) . The higher conductivity of MTT2 - based 
were green . films was because of the greater level of conjugation in the 
40 
cm 
45 -1 cm 
TABLE 1 
Surface and physicochemical properties of the polymer films 
Ra ( um ) Rq ( um ) X. ( % ) Conductivity , o ( S cm ! ) 
Glass substrate 
MTT1 undoped 
MTT1 doped with CSA 
MTT2 undoped 
MTT2 doped with CSA 
0.730 0.153 
0.760 0.299 
0.760 + 0.516 
0.700 + 0.018 
0.475 + 0.009 
0.905 + 0.182 
3.272 6.352 
1.020 + 0.637 
0.085 + 0.024 
0.060 + 0.014 





N / A 
1.59 x 10-8 + 28 % 
2.49 x 10-8 + 33 % 
7.32 x 10-8 + 32 % 
8.55 x 10-8 + 32 % 
" As determined by XRD . 
Not applicable . 
60 
IR spectra of the films recorded in attenuated total reflec backbone of hexaaniline than in tetraaniline . These conduc 
tance ( ATR ) mode revealed subtle differences in the hierar tivities are lower than those of mammalian tissues ( typically 
chical supramolecular assembly of the polymers , with evi 210-4 Scm - 1 ) 35-37 that should enable the controlled delivery 
dence of both a - helices and B - sheets in all spectra ( FIGS . of a drug upon the application of an electrical potential to the 
5A - D ) , , 27-29 with the a - helices induced by HFIP and the 65 EAPs . intermolecular B - sheets being partially responsible for the We studied the release profiles of the anti - inflammatory 
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( PBS ) in the absence or presence of an electrical stimulus 21 ° C. , with a 1 cm- resolution and 64 scans ( corrected for 
using the experimental setup depicted in FIG . 7. Cyclic background and atmosphere using OMNIC software pro 
voltammograms ( FIGS . 8A - C ) of the DMP - doped films of vided with the spectrometer ) . 
MTT1 presented a redox process at ca. 0.26 V ( leucoemer 
aldine to emeraldine 1 transition ) , whereas those for MTT25 SYNTHESIS OF NITRO - TERMINATED ANI 
presented a process at 0.42 V ( emeraldine 1 to emeraldine 2 LINE TETRAMERS ( O2N - A74 - NO2 ) 
transition ) , confirming the greater conjugation in the back 
bone of the longer oligomers ( potentials are reported vs. a The synthesis of the nitro - terminated aniline tetramers 
Ag / AgCl reference electrode calibrated with ferrocen was carried out in accordance with the literature and ana 
emethanol ) . lytical data were in agreement with the literature ( Scheme 
We monitored the release of DMP at specific time points 2 ) . 
spectroscopically , using its characteristic UV absorption at 
242 nm . DMP loadings in the films were at 10 wt % . Passive SYNTHESIS OF AMINE - TERMINATED ANI 
release from films of MTT1 ( FIG . 2 , grey checked bars ) and LINE TETRAMERS ( H2N - AN4 - NH2 ) 
MTT2 ( FIG . 2 , black checked bars ) was observed , however , 
release was moderately enhanced by the application of an The synthesis of the amine - terminated aniline tetramers 
electrical stimulus ( FIG . 2 ; MTT1 grey bars , MTT2 black was carried out in accordance with the literature and ana 
bars ) , typically by 10 to 20 % for the first five rounds of lytical data were in agreement with the literature ( Scheme 
stimulation , after which the profiles for MTT1 in the 2 ) .2 SYNTHESIS OF NITRO - TERMINATED ANI 
absence / presence of stimulation was observed to be equal LINE HEXAMERS ( O2N - ANG - NO2 ) 
which suggests that it is more prone to spontaneous de The synthesis of the nitro - terminated aniline hexamers 
was carried out in accordance with the literature and ana doping than the ore highly conjugated MTT2 . We believe 
that the release profiles could be improved by tuning both lytical data were in agreement with the literature ( Scheme the length of the electroactive oligoaniline , the ratio of 25 2 ) .23 , 
electroactive to non - electroactive peptide blocks , and the SYNTHESIS OF AMINE - TERMINATED ANI identity of the non - electroactive peptide ( i.e. composition LINE HEXAMERS ( H2N - ANG - NH2 ) and sequence of amino acids ) . 
Analogous electroactive block copolymers incorporating 
CSA - doped oligoalanines have been shown to support the The synthesis of the amine - terminated aniline hexamers 
was carried out in accordance with the literature and ana adhesion of a variety of cells including fibroblasts , keratino 
cytes , osteoblasts , PC12 cells and Schwann cells.11 We lytical data were in agreement with the literature ( Scheme 
found that cell viability for the HDFs cultured on the films 
of MTTs was comparable , and indeed somewhat better than SYNTHESIS OF L - ALANINE TCP controls ( FIG . 3A ) . However , the adhesion of human N - CARBOXYANHYDRIDE ( ALA - NCA ) dermal fibroblasts ( HDFs ) to films of undoped or CSA doped MTT , was poor by comparison with commercially The synthesis of the L - alanine N - carboxyanhydride was 
available Corning Costar® tissue culture plate ( TCP ) con 
trols as determined using the AlamarBlue® assay ( FIG . 3B ) , 40 data were in agreement with the literature ( Scheme 3 ) .25 carried out in accordance with the literature and analytical 
and cells had relatively rounded morphologies indicative of 
poor cell adhesion ( FIGS . 4A and 4B ) , particularly by SYNTHESIS OF TETRAANILINE - BASED 
comparison with TCP controls ( FIG . 9 ) . Interestingly , HDF MOLECULAR TONGUE TWISTER 1 ( MTT1 ) 
adhesion to films of undoped or CSA - doped MTT2 was 
moderately better , with cells more likely to adopt a spread 45 MTT1 was synthesised by adaption of the literature 
morphology ( FIGS . 4C and 4D ) . For certain applications , 1 molar eq . of amine - terminated aniline 
non cell - adhesive biomaterials are interesting candidates , tetramer ( H2N - AN - NH2 ) and 10 molar eq . L - alanine N - car such as for the manufacture of anti - adhesion membranes ; 38 boxyanhydride ( ALA - NCA ) were stirred in anhydrous DMF however , for other applications ( e.g. tissue scaffolds ) cell ( solids at 100 mg mL- ? ) at room temperature under an inert adhesion is beneficial . We believe that cell adhesion could be 50 
improved by incorporating cell adhesive peptides ( e.g. , the atmosphere of argon for 4 days . The product was precipi 
ubiquitous RGD ) 10,16,39-41 in the backbone of such EAPs . tated in diethyl ether , the solids isolated by filtration , washed 
with diethyl ether and dried under high vacuum for 48 hours . 
EXPERIMENTAL The solids were suspended in hexafluoroisopropanol ( HFIP ) 
55 and the HFIP - soluble fraction was extracted by shaking the 
Materials and Synthetic / Analytical Methods suspension in 15 mL of HFIP at 1000 rpm for 24 hours , after 
Unless otherwise stated , all chemicals were of ACS grade , which the solids were removed by filtration and the product 
purchased from Sigma - Aldrich and used as received without isolated by evaporation of the HFIP with a rotary evaporator , 
further purification . ' H and 13C NMR spectra were recorded followed by drying under high vacuum for 48 hours 
on an Agilent 600 MHz NMR spectrometer , using residual 60 ( Scheme 1 ) . MTT1 was isolated in a yield of 10 mass % , 
solvent ' H peaks as internal references for the H NMR relative to the total mass of starting materials ( ALA - NCA 
spectra and the solvent 13C peaks as references for the 130 and H2N - A74 - NH2 ) . 1H NMR ( 600 MHz , HFIP - d2 ) : 
NMR spectra . The following notation is used for the ' H 8H = 7.57-6.58 ( br m , 16H , Ar - H ) , 4.14 ( br m , 10H , 
NMR spectral splitting patterns : multiplet ( m ) , broad ( br ) . CHCH3 ) , 1.37 ( br m , 30H , CH3 ) . IR ( ATR ) vmax cm 
Infrared spectroscopy was carried out on a Thermo Scien- 65 1648 ( C = 0 , amide 1 ) , 1560 ( C = N and C = C stretch , 
tific Nicolet 380 FT - IR Spectrometer ( Thermo Fisher Sci oligoaniline ) , 1530 ( C = 0 , amide 2 ) , 1496 ( C — C stretch , 
entific Inc. , USA ) . Spectra were recorded in ATR mode at oligoaniline ) . 
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SYNTHESIS OF HEXAANILINE - BASED experiment at 10 V. The electrodes were moved to different 
MOLECULAR TONGUE TWISTER 2 positions after each measurement , and the current passed 
was recorded in at least five different positions . The resis 
MTT2 was synthesised by adaption of the literature tance ( R , 2 ) of the films was determined in accordance with 
methodology . 1 molar eq . of amine - terminated aniline 5 equation 1 : 
hexamer ( H2N - ANG - NH2 ) and 10 molar eq . L - alanine N - car boxyanhydride ( ALA - NCA ) were stirred in anhydrous DMF 
( solids at 100 mg mL- ? ) at room temperature under an inert The resistivity ( 92 / cm ) of the films was determined in 
atmosphere of argon for 4 days . The product was precipi accordance with equation 2 : 
tated in diethyl ether , the solids isolated by filtration , washed 10 p = Rwt / L ( 2 ) with diethyl ether and dried under high vacuum for 48 hours . 
The solids were suspended in hexafluoroisopropanol ( HFIP ) In which : w corresponds to the width of the film in cm ( 2.5 
and the HFIP - soluble fraction was extracted by shaking the cm ) ; t corresponds to the thickness of the film in cm ( as 
suspension in 15 mL of HFIP at 1000 rpm for 24 hours , after determined via profilometry ) ; and L corresponds to the 
which the solids were removed by filtration and the product 15 length of the film in cm ( 0.5 cm ) . The conductivity ( S / cm ) isolated by evaporation of the HFIP with a rotary evaporator , of the films was determined in accordance with equation 3 : 
followed by drying under high vacuum for 48 hours 
o = 1 / p ( 3 ) ( Scheme 1 ) . MTT2 was isolated in a yield of 9 mass % , 
relative to the total mass of solids ( ALA - NCA and H2N X - Ray Diffraction ( XRD ) 
AN - NH2 ) . 1H NMR ( 600 MHz , HFIP - d2 ) : 8H = 7.57-6.58 20 XRD data was collected on a Rigaku R - Axis Spider ( br m , 24H , Ar - H ) , 4.14 ( br m , 26H , CHCH3 ) , 1.31 ( br m , diffractometer with an image plate detector using a graphite 
78H , CH3 ) . IR ( ATR ) vmax cm - l 1644 ( C = 0 , amide 1 ) , monochromator with CuKa radiation ( a = 1.5418 Å ) at room 
1560 ( C = N and C = C stretch , oligoaniline ) , 1532 ( C = O , temperature . The instrument was controlled using Rapid / 
amide 2 ) , 1496 ( C — C stretch , oligoaniline ) . XRD diffractometer control software ( Rapid / XRD Version 
Film Preparation and Characterization 25 2.3.8 . , Rigaku Americas Corporation , The Woodlands , Tex . ) . 
Film Preparation The integration of the two dimensional data into a one 
Films were prepared by casting solutions of the copoly dimensional pattern was accomplished using 2DP ( 2DP 
mers in hexafluoroisopropanol ( HFIP , typically 0.05 g / mL ) Version 1.0 . , Rigaku Americas Corporation , The Woodlands , 
onto HFIP insoluble substrates , ( e.g. , microscope slides with Tex . ) . Percentage crystallinities were determined by taking 
dimensions of 2.5 cmx5 cm or glassy carbon electrodes with 30 the ratio of the crystalline area to the amorphous area in the 
surface areas of 0.0314 cm² ) . The solvent was allowed to XRD spectrum . 
evaporate in a fume hood , and the films were subsequently In Vitro Drug Delivery and Cell Culture Studies 
dried under vacuum for 48 hours at room temperature . The Preparation of Drug Doped Films 
polymers were doped with camphorsulfonic acid ( CSA ) by Films of ca. 3-4 mg were prepared by casting solutions of 
the addition of CSA to the HFIP solution prior to casting on 35 the polymers and DMP ( at a mass ratio of 10 : 1 polymer : 
microscope slides . Unless otherwise stated CSA doping was DMP ) in hexafluoroisopropanol ( typically 0.05 g / mL ) onto 
at a mass ratio of 1:10 CSA : MTT . a glassy carbon electrode ( 0.0314 cm ?, CH Instruments , Profilometry Inc. ) . The solvent was allowed to evaporate in a fume hood , 
Profilometry was carried out using a Veeco Dektak 150 and the films were subsequently dried under vacuum for 48 
Stylus Profilometer ( Veeco Instruments Inc. , NY ) fitted with 40 hours at room temperature . 
a diamond stylus tip . The profilometer was isolated on an air Drug Delivery Studies 
table to reduce ambient vibrations . The profilometer was Voltammetry experiments were carried out using a 
operated at 10 mg of stylus force , and used to record profiles CH16273C electrochemical analyzer ( CH Instruments , Inc. ) . 
of distances of ca. 1 cm , recording data points every 555 nm . Phosphate buffered saline ( PBS , pH 7.0 ) was deoxygenated 
Data analysis was carried out with the software provided by 45 for 10 minutes with argon before the electrochemical mea 
the manufacturer , which allowed the determination of the surements were made . Electrochemically - triggered release 
thickness and roughness of the films . The surface roughness ( i.e. , de - doping ) of DMP from the films deposited on glassy 
parameters are analyzed and reported in accordance with the carbon substrates by potential cycling , was achieved using a 
ISO 25178 series . The average roughness ( Ra ) is the arith three - electrode system consisting of one polymer film 
metic average of the deviation from the mean line , and is the 50 coated glassy carbon working electrode , a Pt mesh counter 
most used international parameter of roughness , and the electrode , and an Ag / AgCl reference electrode in 4 mL PBS . 
root - mean - square roughness ( Rq ) is based upon this . Prior to each experiment there was a 10 s “ quiet time ” , the 
Conductivity Determination initial potential was 0 V , the high potential was 0.7 V , the low 
The conductance of films of the polymers were measured potential was -0.5 V , the initial scan was positive , the 
in accordance with protocol IPC - TM - 650 , number 2.5.17.2 55 current was measured at intervals of 0.001 V , the scan rate described by the Institute for Interconnecting and Packaging used in all experiments was 50 mV s - 1 , and this stimulation 
Electronic Circuits . Films supported on glass slides were lasted 62 seconds . The films were allowed to rest for 14 
examined by chronoamperometry using a CHI900C electro minutes after which the quantity of DMP in solution was 
chemical workstation ( CHI instruments , Austin , Tex . ) . Chro quantified by UV spectroscopy . The medium was unchanged 
noamperometric measurements were made with a two - point 60 between cycles , and the data are reported as cumulative 
probe system ( copper alligator clips ) , by connecting counter release as a percentage of the total mass of drug in the film 
and reference electrodes together . Briefly , two thin strips of over the period of the experiment . These data are compared 
adhesive - backed copper tape ( Ted Pella , Inc. , Redding , to passive DMP release from unstimulated films measured 
Calif . ) were attached to the films , parallel to one another , every 15 minutes . DMP release was quantified by UV 
separated by a distance of 0.5 cm . The working and counter 65 spectroscopy using a BioTek Epoch® plate reader ( BioTek 
electrodes were clipped on the strips of copper tape , and the US , Winooski , Vt . ) equipped with a Take3 Micro - volume 
current measured for 50 seconds during a potential step Plate and Gen5 v2.04 Software supplied with the plate 
15 
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reader . Two samples of 2 uL were removed from the release integrated into the DNA strands . Fluorescence images of 
medium at specific time points and absorbance readings cells were captured using an Olympus DP80 camera ( Olym 
were carried out at 242 nm ( the characteristic absorbance pus America Inc. , Miami , Fla . , USA ) attached to a fluores band of DMP ) . Absorptions were corrected by subtracting cence microscope ( IX - 70 ; Olympus America Inc. ) running 
the reading of PBS alone from each sample . A standard 5 CellSens 1.12 software ( Olympus America Inc. ) . Cells were 
calibration curve for DMP was plotted to define the quan counted with ImageJ . 
titative relationship between the observed absorbance and 
the concentration of DMP . Prior to the experiment , the mass CONCLUSIONS 
of the drug - doped polymer film on the substrate was deter 
mined by subtracting the mass of the substrate from the mass 10 Herein we described electrically - triggered drug release 
of the polymer - coated substrate . Data are plotted as % DMP from electroactive molecular tongue - twisters ( i.e. , oligoala release relative to the quantity of DMP theoretically in the nine - oligoaniline - oligoalanine ) . The electroactive ABA film at the beginning of the experiment , and all data are the block copolymers based on A ) non - electroactive oligoala average of at least three samples . nines , and B ) electroactive blocks of oligoanilines , repre Cell Culture 
All reagents were purchased from Invitrogen ( Carlsbad , sents a novel platform for drug delivery . The physicochemi 
Calif . ) unless otherwise noted . Human dermal fibroblasts cal properties of the films were characterized by various ( HDFs ) were purchased from Lonza ( Gaithersburg , Md . ) . techniques , and we found that hexaaniline - based MTT2 was 
Commercially available tissue - culture treated Corning® more conductive and appeared to be more electrochemically 
Costar® tissue culture plates were used for control experi- 20 stable towards de - doping than tetraaniline - based MTT1 . 
ments and sections of glass slides coated with polymer films While HDFs cultured on the surfaces of such films adhered 
of ca. 1 cm² ( optionally doped with CSA ) were inserted in weakly , this could be improved by incorporating cell - adhe 
tissue culture plates and sterilized by incubation in 70 % sive moieties.39-41 While imperfect , such EAPs represent 
ethanol solution , followed by exposure to UV for 30 min valuable lead structures for the development of materials 
utes . After sterilization , films were incubated for 30 minutes 25 that enable us to deliver drugs with clinically relevant 
under 3 mm of Dulbecco's Modified Eagle Medium chronopharmacologies , and facilitate the treatment of con ( DMEM ) supplemented with 10 % fetal bovine serum , 100 U ditions with specific chronobiologies ( e.g. infectious dis 
ml- penicillin , 100 ug ml - l streptomycin , 0.25 ug ml - 1 eases , pain ) . We believe that it should be possible to ratio 
amphotericin , 0.1 mM non - essential amino acids , and 1 ng nally control the release profiles and cell - biomaterial 
ml - 1 basic fibroblast growth factor . Medium was aspirated 30 interactions by tuning the length of the electroactive oligoa 
and replaced prior to HDF seeding . Cell viability before niline , the ratio of electroactive to non - electroactive peptide 
starting the experiment was determined by the Trypan Blue blocks , and the identity of the non - electroactive peptide ( i.e. ( Sigma , USA ) exclusion method , and the measured viability composition and sequence of amino acids ) . Specifically , 
exceeded 95 % in all cases . Cells were seeded on tissue increasing the length of the oligoalanine segments should 
culture treated Corning® Costar® tissue culture plates at 35 render them more conductive and electrochemically stable 
10,000 cells per cm2 , and all other substrates ( i.e. MTT ( i.e. less likely to be spontaneously de - doped in biological 
based films ) at 2,500 cells per cm² , under 3 mm of medium , milieu ) . The composition and sequence of amino acids in the 
and incubated at 37 ° C. , 95 % humidity , and a CO2 content non - electroactive peptide dictate the charge and hydropho 
of 5 % . The cell adhesion and quantification studies were bicity of the materials , which play roles in the self - assembly 
carried out using the AlamarBlue® assay in accordance with 40 of the peptides ( i.e. , hydrogen bonding interactions , electro 
the manufacturers instructions . After 2 days the medium was static interactions ) and protein deposition on their surfaces 
aspirated and the films were washed gently with PBS , which may be important for cell adhesion . Cell - biomaterial 
followed by the addition of fresh medium containing 10 % interactions could be controlled through the inclusion of 
V / v AlamarBlue® reagent . After 2.5 hours of culture , the cell - adhesive peptides ( e.g. , RGD , YIGSR , KQAGDV , 
medium was aspirated and replaced with fresh medium , and 45 KHIFSDDSSE , KRSR ) , 39-41 and protease - labile domains 100 uL of the aspirated medium containing the Alamar ( APGL , VRN , or indeed oligoalanines such as those in the 
Blue® reagent was placed in a 96 well plate , and the backbone of MTT1 and MTT2 that are degraded by 
fluorescence was measured with a fluorimeter ( Synergy HT elastase ) , 40 potentially facilitate their degradation in vivo . 
Multi - Mode Microplate Reader , Biotek US , Winooski , Vt . ) . Furthermore , molecules with higher ratios of electroactive to 
Two controls were considered during the measurement of 50 non - electroactive peptide blocks should be more conductive , the fluorescence : the first was wells containing the medium and the inclusion of charged amino acids may facilitate the 
alone ( i.e. no cells of AlamarBlue® reagent ) , which was not inclusion of cationic drugs ( antibacterials , antiarrhythmics , 
fluorescent ; and the second was wells that contained the etc. ) . 
AlamarBlue® reagent but no cells ( used for background 
correction ) . Numbers of cells adhered to the various surfaces 55 REFERENCES 
studied herein are reported relative to their initial seeding 
density , which was assigned an arbitrary value of 100 % . A. S. Mandal , N. Biswas , K. M. Karim , A. Guha , S. 
After another 2 days ( i.e. at 4 days after initial seeding ) the Chatterjee , M. Behera and K. Kuotsu , J. Controlled 
viability of the cells was evaluated using a LIVE / DEAD® Release , 2010 , 147 , 314 . 
Viability / Cytotoxicity Kit for mammalian cells ( Molecular 60 B. Chertok , M. J. Webber , M. D. Succi and R. Langer , Mol . 
Probes , Eugene , Oreg . ) . The medium was removed and the Pharm . , 2013 , 10 , 3531 . 
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